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Abstract
Background: In patients requiring surgical resection for malignant biliary jaundice, it is unclear if preoperative
biliary drainage (PBD) would improve mortality and morbidity by restoration of biliary flow prior to operation. This
is a meta-analysis to pool the evidence and assess the utility of PBD in patients with malignant obstructive jaundice.
The primary outcome is comparing mortality outcomes in patients with malignant obstructive jaundice undergoing
direct surgery (DS) versus PBD. The secondary outcomes include major adverse events and length of hospital stay
in both the groups.
Methods: Studies using PBD in patients with malignant obstructive jaundice were included in this study. For the
data collection and extraction, articles were searched in MEDLINE, PubMed, Embase, Cochrane Central Register of
Controlled Trials & Database of Systematic Reviews, etc. Pooled proportions were calculated using both
Mantel-Haenszel method (fixed effects model) and DerSimonian-Laird method (random effects model).
Results: Initial search identified 2230 reference articles, of which 204 were selected and reviewed. Twenty-six
studies (N = 3532) for PBD in malignant obstructive jaundice which met the inclusion criteria were included in this
analysis. The odds ratio for mortality in PBD group versus DS group was 0.96 (95 % CI = 0.71 to 1.29). Pooled
number of major adverse effects was lower in the PBD group at 10.40 (95 % CI = 9.96 to 10.83) compared to 15.56
(95 % CI = 15.06 to 16.05) in the DS group. Subgroup analysis comparing internal PBD to DS group showed lower
odds for major adverse events (odds ratio, 0.48 with 95 % CI = 0.32 to 0.74).
Conclusions: In patients with malignant biliary jaundice requiring surgery, PBD group had significantly less major
adverse effects than DS group. Length of hospital stay and mortality rate were comparable in both the groups.
Keywords: Preoperative biliary drainage, Malignant obstructive jaundice, Pancreatic head cancer, Peri-ampullary
malignancy, Cholangiocarcinoma, Pancreaticoduodenectomy, Malignant biliary stricture, Meta-analysis, Systematic
review
Background
Malignancies obstructing the biliary tract or ampulla of
Vater can cause obstructive jaundice. Close to 20 % of
these malignancies are resectable at the time of presen-
tation [1–3]. These malignancies include cancers of the
biliary tract, cancers of the head and neck of the pan-
creas, cancers of the second part of duodenum, and
cancer of the ampulla of Vater. Biliary obstruction alters
the normal physiology and affects multiple organ sys-
tems that include but are not limited to cardiac, renal,
hematologic, and hepatic dysfunction [4–7]. Hyperbiliru-
binemia is a potential risk factor that might be associ-
ated with poor surgical outcomes [8–10].
Evidence suggests that biliary drainage may improve
immune function and nutritional status and reduce the
risk of infection [11–13]. Patients with malignant ob-
structive jaundice undergoing surgery are at increased
risk of postoperative complications [14, 15]. As an at-
tempt to reduce these complications, preoperative biliary
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drainage was pursued in these patients. The idea was to
restore normal physiology by improving the biliary
drainage. The “Whipple’s surgery” in 1935 was a two-
staged surgery intended to facilitate the same, i.e., biliary
drainage [16]. Numerous studies have been published
since then that evaluated the efficacy of preoperative bil-
iary drainage in these patients.
Preoperative biliary drainage (PBD) can be achieved by
an internal or external approach. Internal biliary drain-
age is achieved by endoscopic placement of a biliary
stent and endoscopic sphincterotomy. External biliary
drainage is performed via a fluoro-guided percutaneous
transhepatic approach. Previous studies have shown no
mortality benefit from preoperative biliary drainage in
these patients; however, it was associated with increased
morbidity [17, 18]. As mentioned earlier, there is no evi-
dence of benefits from the use of preoperative biliary
drainage. This being said, as many as 6 out of 10 pa-
tients still end up getting some sort of biliary drainage
procedure [19]. It is done as a temporary measure to re-
lieve jaundice in patients waiting for surgery (either due
to prolonged waiting period or delay due to preoperative
assessment) and post-endoscopic retrograde cholangio-
pancreatography prophylactic biliary stent placement to
prevent cholangitis.
The most recent meta-analysis by Fang et al. [17] in-
cluded only randomized controlled trials (RCT). Meta-
analysis done by Sewnath et al. [18] in 2002 included
RCTs and retrospective cohort studies. Newer studies
have been published that have not been included in the
prior meta-analyses. In our meta-analysis, we sought to
include all the available studies [20–45] including RCTs
and retrospective cohort studies evaluating the efficacy
of preoperative biliary drainage in patients with malig-
nant obstructive jaundice. The primary outcome is to
compare mortality in patients with malignant obstructive
jaundice undergoing direct surgery (DS) versus pre-
operative biliary drainage. The secondary outcomes in-
clude major adverse events (morbidity) and length of
hospital stay in both the groups.
Methods
Study selection criteria
Studies using preoperative biliary drainage in patients
with malignant obstructive jaundice were included in
this study. Biliary drainage should have been achieved
via an internal approach, an external approach, or both.
Studies must have compared outcomes in both the
wings. Studies that looked only at one wing (non-com-
parison studies) were excluded from this analysis.
Data collection and extraction
Articles were searched in MEDLINE, PubMed, Ovid
journals, Embase, Cumulative Index for Nursing and
Allied Health Literature, ACP Journal Club, DARE,
International Pharmaceutical Abstracts, old MEDLINE,
MEDLINE Non-Indexed Citations, OVID Healthstar,
and Cochrane Central Register of Controlled Trials
(CENTRAL). The search was performed for the years
1966 to December 2015. Abstracts were manually
searched in the major gastroenterology journals for the
past 3 years. Study authors for the abstracts included in
this analysis were contacted when the required data for
the outcome measures could not be determined from
the publications. The search terms used were preopera-
tive biliary drainage, malignant obstructive jaundice,
pancreatic head cancer, peri-ampullary malignancy, chol-
angiocarcinoma, pancreaticoduodenectomy, malignant
biliary stricture, mortality, morbidity, length of hospital
stay, complications, meta-analysis, and systematic re-
view. Two authors (HM and SP) independently searched
and extracted the data into an abstraction form. Any dif-
ferences were resolved by mutual agreement. The agree-
ment between reviewers for the collected data was
quantified using the Cohen’s k [46].
Quality of studies
Clinical trials designed with a control and treatment
arms can be assessed for quality of the study. A number
of criteria have been used to assess this quality of a study
(e.g., randomization, selection bias of the arms in the
study, concealment of allocation, and blinding of outcome)
[47, 48]. There is no consensus on how to assess studies
Fig. 1 Flow chart with search results and selection criteria
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designed without a control arm. Hence, these criteria do
not apply to studies without a control arm [48].
Statistical methods
This meta-analysis was performed by calculating pooled
proportions. First the individual study proportion of
mortality rates, overall major adverse effects, and length
of hospital stay were transformed into a quantity using
Freeman-Tukey variant of the arcsine square root trans-
formed proportion. The pooled proportion is calculated
as the back-transform of the weighted mean of the
transformed proportions, using inverse arcsine variance
weights for the fixed effects model and DerSimonian-
Laird weights for the random effects model [49, 50]. For-
est plots were drawn to show the point estimates in each
study in relation to the summary pooled estimate. The
width of the point estimates in the forest plots indicates
the assigned weight to that study. The heterogeneity
among studies was tested using Cochran’s Q test based
upon inverse variance weights [51]. If the p value is >0.10,
it rejects the null hypothesis that the studies are heteroge-
neous. The effect of publication and selection bias on the
summary estimates was tested by both Harbord-Egger
bias indicator [52] and Begg-Mazumdar bias indicator
[53]. Also, funnel plots were constructed to evaluate po-
tential publication bias using the standard error and diag-
nostic odds ratio [54, 55]. Microsoft Excel 2013 software
was used to perform statistics for this meta-analysis.
Results
Initial search identified 2230 reference articles, of which
204 articles were selected and reviewed. Data was
Table 1 Basic characteristics of the included studies




1 Morris-Stiff et al. 2011 [20] UK Prospective cohort analysis Internal and External 152/128 280 118 162
2 van der Gaag et al.
2010 [21]
USA Randomized controlled trial Internal and External 119/83 202 106 96
3 Coates et al. 2009 [22] USA Retrospective cohort analysis Internal and External 48/42 90 56 34
4 Anderson et al. 2004 [23] Republic of
South Africa
Single center observational study Internal and External 4/2 6 6 0
5 Pisters et al. 2001 [24] USA Retrospective cohort analysis Internal and External 164/136 300 207 93
6 Sewnath et al. 2001 [25] Netherlands Retrospective cohort analysis Internal 148/142 290 232 58
7 Martignoni et al.
2001 [26]
Switzerland Retrospective cohort analysis Internal and external 140/117 257 99 158
8 Sohn et al. 2000 [27] USA Retrospective cohort analysis Internal and External 297/270 567 408 159
9 Figueras et al. 2000 [28] Spain Retrospective cohort analysis External − 20 11 9
10 Wig et al. 1999 [29] India Randomized controlled trial External 20/20 40 20 20
11 Povoski et al. 1999 [30] USA Retrospective cohort analysis Internal and external 134/106 240 126 114
12 Hochwald et al. 1999 [31] USA Retrospective cohort analysis Internal and external 40/31 71 42 29
13 Heslin et al. 1998 [32] USA Retrospective cohort analysis Internal and external 41/33 74 39 35
14 Marcus et al. 1998 [33] USA Retrospective cohort analysis Internal 32/20 52 22 30
15 Karsten et al. 1996 [34] Netherlands Retrospective cohort analysis Internal and external 152/89 241 184 57
16 Chou et al. 1996 [35] Taiwan Randomized controlled trial Internal and external 50/43 93 26 67
17 Lai et al. 1994 [36] Hong Kong Randomized controlled trial Internal 59/28 87 43 44
18 Bakkevold et al. 1993 [37] Norway Retrospective cohort analysis Internal and external − 108 35 73
19 Sirinek and Levine 1989 [38] USA Retrospective cohort analysis Internal and external − 138 84 54
20 Lygidakis et al. 1987 [39] Netherlands Retrospective cohort analysis Internal 21/17 38 19 19
21 Pitt et al. 1985 [40] USA Randomized controlled trial Internal and external 45/30 79 37 38
22 Smith et al. 1985 [41] Australia Randomized controlled trial Internal and external 20/10 30 15 15
23 Gundry et al. 1984 [42] USA Retrospective cohort analysis Internal and external − 50 25 25
24 McPherson et al. 1984 [43] UK Randomized controlled trial External − 65 34 31
25 Hatfield et al. 1982 [44] UK Randomized controlled trial External − 57 28 27
26 Denning et al. 1981 [45] USA Retrospective cohort analysis Internal and external 29/28 57 25 32
N-PBD number of patients in the preoperative biliary drainage group, N-DS number of patients in direct surgery group
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extracted from 26 studies (N = 3532) that looked at pre-
operative biliary drainage in malignant obstructive jaun-
dice which met the inclusion criteria. All the studies are
published as full-text articles. Figure 1 shows the search
results. All the pooled estimates given are estimates cal-
culated by the fixed and random effect models.
Table 1 shows the baseline characteristics of the stud-
ies. Of the 26 studies included in this meta-analysis,
eight [21, 29, 35, 36, 40, 41, 43, 44] are randomized con-
trolled trials, one study is a prospective cohort analysis
[20], one study is a single-centered observatory study
[23], and the rest are retrospective studies. The pooled
effects estimated by fixed and random effect models
were similar. The p for chi-squared heterogeneity for all
the pooled accuracy estimates was >0.10.
Mortality and morbidity
The odds of mortality in the preoperative biliary drain-
age group compared to direct surgery group was 0.96
(95 % CI = 0.71 to 1.29). Figure 2 shows the forest plot
showing odds in individual studies. Publication bias
calculated using Harbord-Egger bias indicator gave a
value of −1.04 (95 % CI = −2.22 to 0.15, p = 0.08). The
Begg-Mazumdar indicator gave a Kendall’s tau b value
of −0.23 (p = 0.14). Figure 3 shows the funnel plot for
bias. The agreement between reviewers for the col-
lected data gave a Cohen’s k value of 1.0.
Major adverse events include pancreatitis, cholangitis,
perforation, stent occlusion, pancreaticojejunostomy
leakage, gastrojejunostomy leakage, duodenojejunostomy
leakage, hemorrhage after ERCP or pancreatectomy,
biliary leakage, delayed gastric emptying, myocardial
infarction, portal vein thrombosis, wound infection,
pneumonia, need for repeated laparotomy, and
intraabdominal abscess. Pooled number of major ad-
verse events in preoperative biliary drainage group
was 10.40 (95 % CI = 9.96 to 10.83) compared to 15.56
(95 % CI = 15.06 to 16.05) in the direct surgery group.
Fig. 2 Forest plot: individual study proportions and the pooled estimate of odds ratio for mortality in the PBD group versus the DS group. (Fixed effects)
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The Begg-Mazumdar indicator gave a Kendall’s tau b
value of 0.69 (p = <0.0001) and 0.49 (p = 0.0006) in the
PBD and DS groups, respectively. Figures 4 and 5
show the forest plots of the major adverse event effect
size in individual studies, in the PBD and DS groups,
respectively.
Length of hospital stay
Pooled fixed effect size of length of postoperative hos-
pital stay in preoperative biliary drainage followed by
surgery group was 15.20 days (95 % CI = 14.56 to 15.82)
compared to 16.20 days (95 % CI = 15.30 to 17.05) in the
direct surgery group. The Begg-Mazumdar indicator
gave a Kendall’s tau b value of 0.67 (p = 0.013) and 0.67
(p = 0.013) in the PBD and DS groups, respectively. Pub-
lication bias calculated using Harbord-Egger bias indica-
tor gave a value of 5.3 (95 % CI = 1.87 to 8.73, p = 0.08)
and 5.5 (95 % CI = 2.03 to 8.90, p = 0.007) in the PBD
and DS groups, respectively.
Internal PBD versus DS subgroup analysis
Subgroup analysis was performed on studies that com-
pared internal PBD and DS in patients with malignant
biliary strictures. Four studies [25, 33, 36, 39] were in-
cluded in this analysis. The total number of patients in
this subgroup (n) was 467, with 316 patients in the in-
ternal PBD group. The median age of patients in this
subgroup was 65 years, with predominantly male popu-
lation (64 %). The pooled odds ratio for major adverse
effects in the internal PBD group compared to the DS
group was 0.48 (95 % CI = 0.32 to 0.74). Figure 6 is a for-
est plot that displays the same data. Due to the limited
data available, we were not able to generate any
meaningful results in regard to the mortality and length
of hospital stay.
External/percutaneous transhepatic PBD versus DS
subgroup analysis
Subgroup analysis was also performed on studies that
compared percutaneous transhepatic PBD and DS in
patients with malignant biliary strictures. Four studies
[28, 29, 43, 44] were included in this analysis. The total
number of patients in this subgroup (n) was 182, with 93
patients in the percutaneous transhepatic PBD group. The
median age of patients in this subgroup was 62 years, with
predominantly male population (61 %). The pooled odds
ratio for mortality in the percutaneous transhepatic PBD
group compared to the DS group was 0.98 (95 % CI = 0.46
to 2.10). I2 (inconsistency) = 21.4 % (95 % CI = 0 % to
74.2 %). Egger, bias = −2.98 (95 % CI = −5.80 to −0.15) p =
0.04. Figure 7 is a forest plot that displays the same data.
Odds ratio for major adverse events in percutaneous
transhepatic PBD group versus DS group was 1.50 (95 %
CI = 0.85 to 2.65). I2 (inconsistency) = 88.5 % (95 % CI =
68.8 to 93.8 %). Egger, bias = 3.70 (95 % CI = −18.41 to
25.81) p = 0.54. Due to the limited data available, we were
not able to generate any meaningful results in regard to
the length of hospital stay and individual adverse events.
Discussion
Based on literature review, it is unclear if PBD is beneficial
to the patients with malignant biliary strictures. On the
contrary, this analysis showed that the PBD group might be
associated with the overall less major adverse events com-
pared to the DS group. The internal PBD group had statis-
tically significant reduction in the major adverse events
Fig. 3 Funnel plot for publication bias assessment (odds ratio for mortality)
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compared to the DS group. There was no difference in
mortality and length of hospital stay in both the groups
Surgical procedures to treat these malignancies are as-
sociated with high complication rates even with good
surgical expertise at high volume centers. With the ad-
vancements in medical and surgical fields, the postoper-
ative complications have relatively come down. van der
Gaag et al. [21] showed that the PBD group was associ-
ated with slightly lower surgery related mortality com-
pared to the DS group; however, there was no difference
in the overall survival time.
Biliary stenting attempts at restoring the normal physi-
ology. Sometimes even with stenting, the bilirubin level
and hepatic function may not come back to normal due
to the inadequate duration of stenting or due to the
damage already done by the malignant obstruction. The
trials had a wide range (10–32 days) of duration of PBD.
The longer duration could be from the extended waiting
time for surgery or due to the slow improvement in hep-
atic function with PBD. After a biliary stent has been
placed, hepatic function takes close to 4–6 weeks to re-
turn to normal even though the bilirubin levels might
fall more quickly. There are studies that showed that
some of the physiological functions might not return to
baseline even after 6 weeks of stenting [43, 56–59]. Due
to the nature of data that was available from the trials,
we were unable to perform a subgroup analysis based on
the duration of PBD. Shorter duration stenting might
not provide enough time to completely reverse the hep-
atic function. On the other hand, longer duration of
Fig. 4 Forest plot: individual study proportions and the pooled estimate of effect size for overall adverse events in the PBD group
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stenting could be associated with stenting-related com-
plications like stent occlusion, infection, migration, and
tumor progression.
In a meta-analysis of randomized controlled trials
done by Fang et al. [17], PBD group showed no mortality
benefit however was associated with increased morbidity
compared to direct surgery group. Another meta-
analysis by Sewnath et al. [18] concluded on almost
similar results. However, our meta-analysis shows that
the PBD group was associated with the overall less major
adverse events compared to the direct surgery group, es-
pecially in patients undergoing internal PBD. A recent
published article [60] mentioned certain clinical situa-
tions where PBD could be indicated when patients had
unresectable cancers or there has been a delay in
surgery.
There are a few limitations to this analysis. Studies in-
cluded have used plastic stents and self-expandable
metal stents. Plastic stents are associated with increased
number of complications and short patency. Due to the
paucity of data, we were not able to compare outcomes
in metallic versus plastic stents [61–67]. Different ap-
proaches of stenting have been used. Internal stenting
was used in four studies [25, 33, 36, 39], and external
stenting was used in four studies [28, 29, 43, 44] whereas
internal and external stenting have been used in rest of
the studies [20–24, 26, 27, 30–32, 34, 35, 37, 38, 40–42,
45]. Suboptimal ERCP expertise in certain studies could
Fig. 5 Forest plot: individual study proportions and the pooled estimate of effect size for overall adverse events in the DS group
Moole et al. World Journal of Surgical Oncology  (2016) 14:182 Page 7 of 11
have affected the outcomes. Few studies included in this
analysis are old, done in 1980s. The surgical procedures,
stenting techniques, and stent types used in these old
studies could be outdated and associated with increased
complications. Different types of surgical techniques
have been used in these trials. Bypass procedure has
been shown to have better outcomes compared to
pancreatoduodenectomy. There is no clear definition for
the optimal duration of PBD prior to surgery. Some au-
thors however support that 4 weeks is an optimal time
duration for PBD. Most of the studies have unclear allo-
cations, and reasons for drop outs from the trials were
unclear. The type of malignancy causing the biliary
obstruction, stage of the malignancy, and presence of
Fig. 6 Forest plot: individual study proportions and the pooled estimate of odds ratio for major adverse events in the internal PBD group versus
the DS group. (Fixed effects)
Fig. 7 Forest plot: individual study proportions and the pooled estimate of odds ratio for mortality in the external PBD group versus the
DS group. (Fixed effects)
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metastasis could have all influenced the results. Location
of the stricture might also influence the outcomes.
Retrospective cohort studies were included in this meta-
analysis along with RCTs.
The strengths of this meta-analysis include the high-
quality methodology of statistical analysis, high-quality
methodology used in individual studies, large number of
studies compared to prior meta-analyses, and the total
number of patients included in this analysis (N = 3532).
Newer trials were included in this analysis adding to the
data that is already present.
Based on the results from our meta-analysis, preopera-
tive biliary stenting has overall less complications com-
pared to the direct surgery group, especially with the use
of internal PBD. This may further translate into less cost
burden and suffering for patients. We could speculate
that PBD could be indicated in certain clinical scenarios
if done under good expertise. PBD could be used in pa-
tients with unresectable malignancies, in patients with
high surgical risk and unfit for surgery, patients with
delay in surgery, and patients awaiting surgery and
undergoing neo-adjuvant therapy. Current meta-analysis
reached slightly different results compared to previous
meta-analysis. This may be due to the results from the
newly published studies included in this meta-analysis,
which were not included in the prior meta-analysis. The
advancement in technological aspects and operative
skills of biliary drainage procedures could have also con-
tributed to these results.
There was no mortality difference in both groups; this
could probably be due to the underlying disease nature
itself. Due to the limited data available on cost-benefit
analysis and quality of life, we could not analyze further
in this regard.
Studies with statistically significant positive results
tend to be published and cited. Additionally, smaller
studies may show larger treatment effects compared to
larger studies. This publication and selection bias may
affect the summary estimates. The bias can be estimated
using Egger bias indicators and the construction of fun-
nel plots, whose shape can be affected by bias. In the
present meta-analysis and systematic review, bias calcu-
lations both Egger [52] and Begg-Mazumdar [53] bias
indicators showed no statistically significant bias. Fur-
thermore, analysis using funnel plots were used to repre-
sent publication bias among the studies included in the
present analysis.
Conclusions
In patients with malignant biliary jaundice requiring sur-
gery, our analysis showed that the preoperative biliary
drainage group had significantly less major adverse ef-
fects than direct surgery group. Length of hospital stay
was comparable in both the groups. There was no clear
mortality benefit with preoperative biliary drainage com-
pared to direct surgery. Subgroup of patients that under-
went internal PBD had statistically significant reduction
in major adverse effects compared to DS group.
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